ASB Consultores LLC Sells 3,018 Shares of Pfizer Inc. (NYSE:PFE)

ASB Consultores LLC lessened its holdings in Pfizer Inc. (NYSE:PFE) by 19.4% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 12,540 shares of the biopharmaceutical company’s stock after selling 3,018 shares during the period. ASB Consultores LLC’s holdings in Pfizer were worth $363,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. China Universal Asset Management Co. Ltd. purchased a new position in shares of Pfizer in the first quarter worth $315,000. Norden Group LLC boosted its holdings in shares of Pfizer by 26.8% during the 1st quarter. Norden Group LLC now owns 30,336 shares of the biopharmaceutical company’s stock valued at $842,000 after purchasing an additional 6,404 shares during the last quarter. Central Pacific Bank Trust Division purchased a new position in shares of Pfizer during the first quarter valued at about $136,000. GSA Capital Partners LLP bought a new stake in shares of Pfizer in the first quarter worth about $439,000. Finally, C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors lifted its position in shares of Pfizer by 97.5% in the first quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors now owns 19,923 shares of the biopharmaceutical company’s stock worth $553,000 after buying an additional 9,835 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

Insider Transactions at Pfizer

In other news, Director Scott Gottlieb purchased 1,000 shares of the stock in a transaction that occurred on Wednesday, October 30th. The stock was purchased at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the acquisition, the director now owns 10,000 shares of the company’s stock, valued at approximately $282,400. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 0.06% of the company’s stock.

Wall Street Analyst Weigh In

PFE has been the subject of several research analyst reports. UBS Group raised their price target on Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a report on Wednesday, July 31st. Evercore ISI upgraded shares of Pfizer to a “strong-buy” rating in a research report on Wednesday, October 30th. Sanford C. Bernstein started coverage on shares of Pfizer in a research note on Thursday, October 17th. They set a “market perform” rating and a $32.00 price target on the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research note on Wednesday, October 23rd. Finally, Wells Fargo & Company upped their target price on shares of Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 31st. Eight investment analysts have rated the stock with a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $33.58.

Pfizer Trading Down 1.2 %

PFE opened at $27.76 on Tuesday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86. The stock’s 50 day moving average price is $29.01 and its 200-day moving average price is $28.63. Pfizer Inc. has a one year low of $25.20 and a one year high of $31.54. The stock has a market cap of $157.31 billion, a price-to-earnings ratio of 37.51, a P/E/G ratio of 0.89 and a beta of 0.67.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. The business had revenue of $17.70 billion for the quarter, compared to analyst estimates of $14.92 billion. Pfizer had a return on equity of 16.40% and a net margin of 7.07%. The business’s revenue was up 31.2% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.17) earnings per share. On average, equities analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be paid a $0.42 dividend. The ex-dividend date is Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a yield of 6.05%. Pfizer’s dividend payout ratio is currently 227.03%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.